Boehringer Will Test How Pradaxa Stacks Up To The Competition In Real-World Study

This article was originally published in Pharmaceutical Approvals Monthly

01 May 2012
News

Emily Hayes @emilykatehayes emily.hayes@informa.com

Executive Summary

Global observational study is assessing real-world experience with Pradaxa and other anticoagulants in patients with newly diagnosed atrial fibrillation who are at risk of stroke. Results are due in 2020.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Related Companies

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical Comparative Effectiveness Clinical Trials

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS005086

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS005086

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Boehringer Will Test How Pradaxa Stacks Up To The Competition In Real-World Study

News

Executive Summary

Related Content

Topics

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert